Alaunos Therapeutics, Inc. Logo

Alaunos Therapeutics, Inc.

Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.

TCRT | US

Overview

Corporate Details

ISIN(s):
US98973P1012
LEI:
Country:
United States of America
Address:
501 E LAS OLAS BLVD, 33301 FORT LAUDERDALE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alaunos Therapeutics, Inc. is a clinical-stage cellular immuno-oncology company focused on developing T-cell receptor (TCR-T) cell therapies for the treatment of solid tumors. The company engineers therapies to target neoantigens that arise from specific genomic 'hotspot' mutations in cancer cells. Its approach utilizes the proprietary hunTR® platform, a discovery engine for expanding its TCR library, and the 'Sleeping Beauty' non-viral transposition technology. This manufacturing process is designed to be rapid, flexible, and cost-effective, aiming to deliver tumor-specific T cells to cancer patients with significant unmet clinical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Alaunos Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alaunos Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alaunos Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
PLUS THERAPEUTICS, INC. Logo
Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.
United States of America PSTV
PMV Pharmaceuticals, Inc. Logo
Developing small molecule therapies targeting p53 mutations to treat cancer.
United States of America PMVP
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
PolyPid Ltd. Logo
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America PYPD
Praxis Precision Medicines, Inc. Logo
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America PRAX
PRECIGEN, INC. Logo
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America PGEN
Precipio, Inc. Logo
Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.
United States of America PRPO

Talk to a Data Expert

Have a question? We'll get back to you promptly.